Recent Updates — ARQT
Arcutis Biotherapeutics reported third-quarter net product revenues of $143.9 million, a 45% increase from the prior year and an 11% rise sequentially, driven by strong demand for its ZORYVE portfolio. The company raised its full-year 2026 net product sales guidance to $535 million–$545 million from the previous range of $525 million–$540 million. Net income was $8.8 million, or $0.07 per share basic and $0.06 diluted, compared to $7.4 million in the same period last year. Operating cash flow remained positive at $18.9 million for the quarter. Arcutis is a commercial-stage biopharmaceutical company focused on developing innovative treatments for immune-mediated dermatological diseases.
The Arcutis Biotherapeutics board increased the authorized number of directors from ten to eleven and appointed Dr. Robert Scott as a Class II director effective October 23, 2026. Dr. Scott joins the Nominating and Corporate Governance Committee and receives an initial stock option award for 20,507 shares plus prorated annual equity valued at approximately $350,000 and cash retainers totaling $55,000. He brings over four decades of pharmaceutical leadership experience, including tenure as Chief Medical Officer at AbbVie and roles at Amgen and Pfizer. Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing treatments for chronic inflammatory skin diseases.
Arcutis Biotherapeutics, Inc. increased its Board of Directors from nine to ten members and appointed Christopher Peetz as a new Class III director, effective July 15, 2026. Mr. Peetz, a biopharmaceutical executive with experience at Mirum Pharmaceuticals and Tobira Therapeutics, will receive an initial stock option award for 21,486 shares and is eligible for a prorated annual equity award valued at approximately $350,000 and a $50,000 cash retainer. Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company focused on developing therapies for chronic inflammatory skin diseases.
Arcutis Biotherapeutics, Inc. held its 2026 Annual Meeting of Stockholders on June 5, 2026, where stockholders' votes on three proposals, including the election of Class III directors (Patrick J. Heron, Neha Krishnamohan, and Todd Franklin Watanabe), the ratification of andhesion to Ernst & Young LLP as independent auditor, and a voting on a non-binding advisory basis of executive officer compensation. The Board of Directors approved revisions to the Amended and Restated Non-Employee Director Compensation Program, Board members are compensated with annual cash and equity compensation. Arcutis Biotherapeutics, Inc. is a biopharmaceutical company that develops and commercializes commercial-stage products for inflammatory and inflammatory-related skin diseases.